The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
Bengaluru startup targets 100+ enterprise clients and global expansion as it aims to transform pharmaceutical sales, marketing, tenders, and distribution using AI agents
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
The move targets long-standing bottlenecks in MSC science, including cell-to-cell variability, immunocompatibility concerns, and inefficient manufacturing workflows
Healthcare operations veteran with over 23 years of experience to lead key initiatives across South India
The hospital chain reported strong growth driven by its Gurugram facility, international patient inflow, and operational efficiencies
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
NEJM study shows strong protection across strains
Subscribe To Our Newsletter & Stay Updated
